| Literature DB >> 24444113 |
Tiina Kortteisto1, Jani Raitanen, Jorma Komulainen, Ilkka Kunnamo, Marjukka Mäkelä, Pekka Rissanen, Minna Kaila.
Abstract
BACKGROUND: Computer-based decision support systems are a promising method for incorporating research evidence into clinical practice. However, evidence is still scant on how such information technology solutions work in primary healthcare when support is provided across many health problems. In Finland, we designed a trial where a set of evidence-based, patient-specific reminders was introduced into the local Electronic Patient Record (EPR) system. The aim was to measure the effects of such reminders on patient care. The hypothesis was that the total number of triggered reminders would decrease in the intervention group compared with the control group, indicating an improvement in patient care.Entities:
Mesh:
Year: 2014 PMID: 24444113 PMCID: PMC3901002 DOI: 10.1186/1748-5908-9-15
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Figure 1Study design. RSVHC is the Repeated Study Virtual Health Check where all decision support rules are run at once and the triggered reminders at the time point are registered; see text for explanation. Both the intervention and control groups were accrued as new individuals visited the health center (i.e. first contact date). Therefore, the starting and end points of follow-up are individual. Occupational healthcare was excluded. (See text and Figure 3 for further explanation).
Figure 3Accumulation of study participants from July 2009 to October 2010.
Examples of the EBMeDS reminders listed according to ICD-10 coding system
| scr00457 | Anticoagulants for atrial fibrillation | 1 | Atrial fibrillation—start warfarin? |
| | | 2 | Atrial fibrillation—consider warfarin? |
| scr00578 | Follow-up of patients with hypertension | 1 | Hypertension—time to check blood pressure? |
| | | 2 | Elevated blood pressure in last measurement—time to check blood pressure? |
| scr00424 | Avoiding decongestants and antihistamines in otitis media in children | 1 | Otitis media—avoid decongestants and antihistamines |
| scr00665 | An abnormal potassium result | 1 | Serum potassium is dangerously out of range (@1)! |
| | | 2 | Serum potassium is out of range (@1) |
| | | 3 | Serum potassium is slightly out of range (@1) |
| scr00107 | GFR below 55 ml/min | 1 | Decreased GFR—no diagnosis of renal failure |
| | | 2 | Decreased GFR and no recent creatinine test—order new creatinine test? |
| scr00664 | Low haemoglobin concentration in adults and adolescents | 1 | Decreased haemoglobin concentration—start investigations? |
| scr00012 | Prevention of osteoporosis in long-term use of glucocorticoids | 1 | Long-term glucocorticoids—add calcium and vitamin D? |
| | | 2 | Long-term glucocorticoids—add a bisphosphonate? |
| scr00094 | Follow-up of high PSA concentration | 1 | High PSA—time to repeat the test? |
| | | 2 | High PSA—time to repeat the test? Note 5-alpha reductase medication |
| scr00425 | SSRIs not indicated for headaches | 1 | Headache—SSRIs are not recommended |
| scr00494 | Inhaled corticosteroids instead of oral steroids for chronic asthma | 1 | Asthma treated with oral steroids—start inhaled steroids? |
| 2 | Asthma treated with courses of oral steroids—start inhaled steroids? | ||
(The decision support rule ID is included to assist interested readers to obtain more information at http://www.ebmeds.org).
The four EBMeDS decision support functions available for the healthcare professional
| These are patient-specific and | |
| The focus of the present paper. | |
| Guideline links | These are shown in accordance with the patient’s diagnosis list and ICD-10 codes. |
| Virtual health check (VHC) | The healthcare professional can run a (clinical) VHC on a selected group of patients. Patient-specific reminders appear on the screen, which can be used |
| Drug alerts | Reminders triggered on prescribing a medication. |
Figure 2The process of eliminating decision support rules from the analyses. The process of elimination from the analyses of non-functioning decision support (DS) rules ending with the 59 rules that were used.
Characteristics of the intervention and the control group in the three models
| | ||||||
|---|---|---|---|---|---|---|
| Number of patients | ||||||
| | 3,836 | 3,734 | 5,983 | 5,928 | 6,435 | 6,360 |
| Age (mean, sd) | ||||||
| | 36.7 (27.8) | 36.8 (27.6) | 35.4 (26.0) | 35.6 (25.8) | 35.4 (25.7) | 35.6 (25.6) |
| Gender (%) | ||||||
| Female | 1,997 (52.1) | 1,960 (52.5) | 3,068 (51.3) | 3,020 (51.0) | 3,305 (51.4) | 3,254 (51.2) |
| Male | 1,839 (47.9) | 1,773 (47.5) | 2,915 (48.7) | 2,907 (49.0) | 3,130 (48.6) | 3,105 (48.8) |
| Number of diagnoses at baseline (%) | ||||||
| 0 | 1,253 (32.7) | 1,220 (32.7) | 2,335 (39.0) | 2,325 (39.2) | 2,576 (40.0) | 2,568 (40.4) |
| 1 | 913 (23.8) | 862 (23.1) | 1,385 (23.2) | 1,344 (22.7) | 1,467 (22.8) | 1,433 (22.5) |
| 2–3 | 995 (25.9) | 985 (26.4) | 1,402 (23.4) | 1,392 (23.5) | 1,490 (23.2) | 1,460 (23.0) |
| 4+ | 675 (17.6) | 667 (17.8) | 861 (14.4) | 867 (14.6) | 902 (14.0) | 899 (14.1) |
| Number of diagnoses at the end of follow-up period (%) | ||||||
| 0 | 458 (11.9) | 460 (12.3) | 1,302 (21.8) | 1,341 (22.6) | 1,643 (25.5) | 1,695 (26.7) |
| 1 | 729 (19.0) | 713 (19.1) | 1,460 (24.4) | 1,425 (24.0) | 1,669 (25.9) | 1,626 (25.6) |
| 2–3 | 1,253 (32.7) | 1,229 (32.9) | 1,820 (30.4) | 1,816 (30.6) | 1,866 (29.0) | 1,820 (28.6) |
| 4+ | 1,396 (36.4) | 1,332 (35.7) | 1,401 (23.4) | 1,346 (22.7) | 1,257 (19.5) | 1,219 (19.2) |
| Number of medications at baseline (%) | ||||||
| 0 | 1,877 (48.9) | 1,809 (48.4) | 3,464 (57.9) | 3,388 (57.2) | 3,797 (59.0) | 3,702 (58.2) |
| 1–5 | 1,363 (35.5) | 1,322 (35.4) | 1.877 (31.4) | 1,870 (31.5) | 1,977 (30.7) | 1,976 (31.1) |
| 6–9 | 368 (9.6) | 372 (10.0) | 403 (6.7) | 425 (7.2) | 413 (6.4) | 434 (6.8) |
| 10+ | 228 (6.0) | 231 (6.2) | 239 (4.0) | 245 (4.1) | 248 (3.9) | 248 (3.9) |
| Number of triggered reminders at baseline (mean, sd) | ||||||
| | 0.30 (0.75) | 0.31 (0.76) | 0.23 (0.65) | 0.23 (0.66) | 0.23 (0.65) | 0.23 (0.67) |
| Number of triggered reminders at the end of follow-up period (mean, sd) | ||||||
| | 0.45 (0.95) | 0.45 (0.93) | 0.27 (0.72) | 0.28 (0.73) | 0.24 (0.68) | 0.25 (0.68) |
| Number of participants with no triggered reminder (%) | ||||||
| 2,733 (71.2) | 2,670 (71.5) | 4,834 (80.8) | 4,781 (80.7) | 5,354 (83.2) | 5,286 (83.1) | |
1Indiv = individual.
Incidence rate ratios (IRR) of the number of triggered reminders by negative binomial regression models using a generalized estimation equation
| | ||||||
|---|---|---|---|---|---|---|
| Indiv_MO12a | ||||||
| Group | 1.002 (0.895 – 1.121) | 0.057 | 0.98 | 1.004 (0.903 – 1.116) | 0.054 | 0.94 |
| Time | 1.014 (1.001 – 1.023) | 0.005 | 0.002 | 1.017 (1.008 – 1.026) | 0.005 | <0.001 |
| Time2 | 1.002 (1.001 – 1.003) | 0.0003 | <0.001 | 1.002 (1.001 – 1.003) | 0.0003 | <0.001 |
| Group × Time | 1.001 (0.995 – 1.008) | 0.003 | 0.73 | 1.002 (0.995 – 1.009) | 0.003 | 0.56 |
| Indiv_MO6b | ||||||
| Group | 1.011 (0.913 – 1.120) | 0.053 | 0.84 | 1.008 (0.923 – 1.101) | 0.045 | 0.86 |
| Time | 1.038 (1.030 – 1.046) | 0.004 | <0.001 | 1.044 (1.036 – 1.052) | 0.004 | <0.001 |
| Group × Time | 0.990 (0.980 – 1.001) | 0.005 | 0.066 | 0.989 (0.978 – 0.9997) | 0.005 | 0.044 |
| Indiv_MO3c | ||||||
| Group | 0.990 (0.895 – 1.094) | 0.051 | 0.84 | 1.013 (0.926 – 1.108) | 0.046 | 0.77 |
| Time | 1.036 (1.024 – 1.050) | 0.007 | <0.001 | 1.046 (1.031 – 1.062) | 0.008 | <0.001 |
| Group × Time | 0.998 (0.980 – 1.017) | 0.009 | 0.86 | 0.996 (0.975 – 1.018) | 0.011 | 0.74 |
aIndiv_MO12 for the study patients with 12 months’ individual follow-up using exchangeable working correlation structure.
bIndiv_MO6 for the study patients with six months’ individual follow-up using exchangeable working correlation structure.
cIndiv_MO3 for the study patients with three months’ individual follow-up using the auto-regressive (AR1) working correlation structure.
dSemi-Robust Huber/White sandwich estimated standard errors.
eAdjusted for age, gender, number of diagnoses and number of medications.
Figure 4Flow chart of study participants. Follow-up time is individual. (Primary outcome measure shown in bold text).